These foods are the heaviest hitters. While GLP-1 drugs have transformed how many people think about weight loss, the ...

Soleno Therapeutics’ stock is soaring on Monday in premarket after a report that Neurocrine is nearing a deal to buy the ...

"ACC 2026: Ventyx’s VTX3232 Phase IIa results show anti-inflammatory benefits in obesity" was originally created and ...

The Endocrine Society has concerns of possible delays in care and other problematic areas of The Lancet Commission’s proposed new obesity framework; a Commission author cites ‘conceptual confusions.’ ...

In phase 3 clinical trials, orforglipron was associated with significant reductions in mean percent body weight compared with placebo in patients with and without type 2 diabetes.

The Lancet obesity framework aims to improve risk assessment but risks delaying treatment and deepening health inequities, according to recent evaluations.

With a second oral GLP-1 for obesity now approved in the U.S., analysts have set to work parsing the blockbuster potential of ...

Cognitive behavioral therapy (CBT) significantly reduces BMI z-scores and improves quality of life among children with obesity.

The Obesity Medicine Association will host its annual conference in San Deigo from April 10-12, diving into the latest ...

Revised diagnostic framework may limit access to early treatment, widen healthcare dispari ...

Novo Nordisk's latest GLP-1 weight loss drug comes in pill form. Its ease of access has drawn in new obesity patients who may ...

Introduction Obesity and its downstream non-communicable diseases (NCDs) are the greatest health challenges of the 21st century, even in low-income and middle-income countries such as India. As ...